5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine
CA 2308323 A1 · Owner: Pfizer Products Inc. · Inventors: Sands, George Harry
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a method of treating migraine in a mammal including a, human, by administering to the mammal a 5HT1 receptor agonist in combination with either a, cyclooxygenase-2 (COX-2) inhibitor or a nonsteroidal antiinflammatory drug (NSAID). It also, relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT, receptor agonist with either a cyclooxygenase-2 (COX-2) inhibitor or a nonsteroidal, antiinflammatory drug (NSAID).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 12, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 12, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 12, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.